Accidental transdermal fentanyl overdose in a child

Fentanyl is a synthetic opioid that provides analgesia for procedures with moderate to severe pain and also can be used to manage acute or chronic pain. Fentanyl is available in several dosing forms and is more widely used as a transdermal patch for the management of chronic pain at home. Accidental exposure to even one dose of fentanyl, especially by children can result in a fatal overdose leading to disturbances of consciousness and/or respiratory depression. A nine-year-old boy was referred to the pediatric emergency department because of disturbed consciousness and respiratory depression. A patch of fentanyl 100 mcg/h was found on the bruised knee during the examination. For treatment, he got naloxone 0.1 mg, infusion therapy and artificial lung ventilation due to respiratory depression. Signs characteristic of acute toxic leukoencephalopathy and hypoxic-ischemic encephalopathy were found on brain magnetic resonance imaging (MRI). After 29 days in the inpatient unit and 120 days of rehabilitation, the patient was discharged home with moderate neurological impairment. Opioid misuse can cause serious life-threatening consequences especially in children resulting in death or severe neurological impairment. When dealing with cases of fentanyl overdose, doctors should keep in mind not only respiratory depression and hypotension, but the presence of toxic leukoencephalopathy as well. These cases may be preventable through better education of prescribers and patients.

Fentanyl; Transdermal patch; Toxic leukoencephalopathy; Opioid overdose; Pediatric

[1] Smith HAB, Besunder JB, Betters KA, Johnson PN, Srinivasan V, Stormorken A, et al. 2022 society of critical care medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically Ill pediatric patients with consideration of the ICU environment and early mobility. Pediatric Critical Care Medicine. 2022; 23: e74–e110.

[2] Kovac AL, Summers KL. Comparison of remifentanil versus fentanyl general anesthesia for short outpatient urologic procedures. Signa Vitae. 2009; 4: 23–29.

[3] Sahyoun C, Cantais A, Gervaix A, Bressan S, Löllgen R, Krauss B. Pediatric procedural sedation and analgesia in the emergency department: surveying the current European practice. European Journal of Pediatrics. 2021; 180: 1799–1813.

[4] Fentanyl. Pediatric drug information 2023. 2023. Available at: https://www-uptodate-com.ezproxy.dbazes.lsmuni.lt/contents/fentanyl-pediatric-drug-information?search=fentanyl%20children&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_pediatric&display_rank=1#F53566883 (Accessed: 01 March 2023).

[5] Hoeffe J, Vogel RG, Ammann RA. Pediatric sedation and analgesia outside the operating room: combining intranasal fentanyl and inhaled nitrous oxide. The Journal of Pediatric Pharmacology and Therapeutics. 2022; 27: 436–442.

[6] Puckey M. Fentanyl. 2022. Available at: https://www.drugs.com/fentanyl.html (Accessed: 01 March 2023).

[7] Hill R, Santhakumar R, Dewey W, Kelly E, Henderson G. Fentanyl depression of respiration: comparison with heroin and morphine. British Journal of Pharmacology. 2020; 177: 254–265.

[8] Kelly E, Sutcliffe K, Cavallo D, Ramos‐Gonzalez N, Alhosan N, Henderson G. The anomalous pharmacology of fentanyl. British Journal of Pharmacology. 2023; 180: 797–812.

[9] Han Y, Cao L, Yuan K, Shi J, Yan W, Lu L. Unique pharmacology, brain dysfunction, and therapeutic advancements for fentanyl misuse and abuse. Neuroscience Bulletin. 2022; 38: 1365–1382.

[10] Skolnick P. Treatment of overdose in the synthetic opioid era. Pharmacology & Therapeutics. 2022; 233: 108019.

[11] Baldo BA. Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity. Archives of Toxicology. 2021; 95: 2627–2642.

[12] Hilado MA, Getz A, Rosenthal R, Im DD. Fatal transdermal fentanyl patch overdose in a child. Cureus. 2020; 12: e6755.

[13] Teske J, Weller JP, Larsch K, Tröger HD, Karst M. Fatal outcome in a child after ingestion of a transdermal fentanyl patch. International Journal of Legal Medicine. 2007; 121: 147–151.

[14] Voigt I. Fatal overdose due to confusion of a transdermal fentanyl delivery system. Case Reports in Critical Care. 2013; 2013: 154143.

[15] Foy L, Seeyave DM, Bradin SA. Toxic leukoencephalopathy due to transdermal fentanyl overdose. Pediatric Emergency Care. 2011; 27: 854–856.

[16] Tormoehlen LM. Toxic leukoencephalopathies. Psychiatric Clinics of North America. 2013; 36: 277–292.

[17] Buck C. Barthel index. 2022. Available at: https://emedicine.medscape.com/article/2172491-overview (Accessed: 28 June 2023).

[18] Stanley TH. The history and development of the fentanyl series. Journal of Pain and Symptom Management. 1992; 7: S3–S7.

[19] Taylor KP, Singh K, Goyal A. Fentanyl transdermal. National library of medicine. National center for biotechnology information. 2023. Available at: https://www-ncbi-nlm-nih-gov.ezproxy.dbazes.lsmuni.lt/books/NBK555968/ (Accessed: 29 June 2023).

[20] Poplawski S, Johnson M, Philips P, Eberhart LH, Koch T, Itri LM. Use of fentanyl iontophoretic transdermal system (ITS) (IONSYS®) in the management of patients with acute postoperative pain: a case series. Pain and Therapy. 2016; 5: 237–248.

[21] Drugs.com. Ionsys. 2022. Available at: https://www.drugs.com/ionsys.html (Accessed: 01 March 2023).

[22] Drugs.com. Fentanyl (Transdermal). 2022. Available at: https://www.drugs.com/cons/fentanyl-transdermal.html (Accessed: 01 March 2023).

[23] Rahman S, Trussell A, Pearson SA, Buckley NA, Karanges EA, Cairns R, et al. Trends in transdermal fentanyl utilisation and fatal fentanyl overdose across Australia (2003–2015). Drug and Alcohol Review. 2022; 41: 435–443.

[24] Ruzycki S, Yarema M. Fentanyl misuse. Canadian Medical Association Journal. 2016; 188: 673.

[25] Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. Journal of Medical Toxicology. 2009; 5: 230–241.

[26] Wolters EC, Stam FC, Lousberg RJ, Wijngaarden GKV, Rengelink H, Schipper ME, et al. Leucoencephalopathy after inhaling “heroin” pyrolysate. The Lancet. 1982; 320: 1233–1237.

[27] Nanan R, von Stockhausen HB, Petersen B, Solymosi L, Warmuth-Metz M. Unusual pattern of leukoencephalopathy after morphine sulphate intoxication. Neuroradiology. 2000; 42: 845–848.

[28] Amaram-Davila J, Mallipeddi T, Reddy A. Opioid prescribing with take-home naloxone: rationale and recommendations. Current Anesthesiology Reports. 2020; 10: 428–435.

[29] Niehaus M, Goodmanson N, Emlet L. Management of opioid overdoses. Opioid Use in Critical Care. 2021; 99: 187–194.

[30] Ali S, Drendel AL. Responsible and safe use of opioids in children and adolescents in the emergency department. Pediatric Emergency Medicine Practice. 2023; 20: 1–24.

[31] Tzemis D, Al-Qutub D, Amlani A, Kesselring S, Buxton JA, Banjo O. A quantitative and qualitative evaluation of the British Columbia take home naloxone program. CMAJ Open. 2014; 2: E153–E161.

[32] Canadian Centre on Substance Use and Addiction. The availability of take-home naloxone in Canada: CCENDU Bulletin. 2022. Available at: https://www.ccsa.ca/ccendu-bulletin-update-stimulant-use-and-related-harms-canada-and-united-states (Accessed: 08 March 2023).

[33] European Monitoring Centre for Drugs and Drug Addiction. Take-home naloxone. 2021. Available at: https://www.emcdda.europa.eu/publications/topic-overviews/take-home-naloxone_en (Accessed: 14 March 2023).

[34] State Medicines Control Agency of Lithuania (vvkt.lt). Medicines consumption. 2021. Available at: https://www.vvkt.lt/index.php?3309762997 (Accessed: 04 March 2023).

[35] Roser M. Our World in Data. 2021. Available at: https://ourworldindata.org/grapher/death-rate-from-opioid-use?tab=table&region=Europe&country=KAZ~KGZ~RWA~USA~CAN~RUS~LTU (Accessed: 08 March 2023).